Search

El pasado 24 de octubre, Mikrobiomik celebró su primer Investor´s Day, reuniendo a profesionales del sector farmacéutico y biotecnológico, socios e inversores. En la jornada se compartieron logros

The new SunLabs facility will be a cutting-edge life sciences research and development hub.

VC funding led by imec.xpand, with significant participation from the EIC Fund (venture arm of the European Innovation Council) and continued support from existing investors Asabys Partners and Aliath

The organisations are collaborating on two studies in the field of severe Legionella infections and antibiotic resistance.

Final data from PORTICO, global Phase IIb vafidemstat trial in BPD,presented at the 37th ECNP annual conference in September

These data consolidate the Barcelona Science Park as one of the most powerful hubs for public innovation in health in Europe and reaffirm its role as a key player in the advancement of socio-economic

Agarose Bead Technologies has enhanced its Burgos facility by boosting its agarose resin production to 100,000 liters annually to position itself as a powerhouse in the novel therapies market.

Spanish company Quibim's QP-Prostate solution, which uses biopsy and MRI data for training, achieves higher accuracy than traditional methods.

ATX-01 is the industry’s first anti-microRNA therapeutic to be investigated in DM1

For the treatment of aggression and social withdrawal.

Peaches starts its phase I-II pilot trial to obtain an advanced biologic drug that will help combat cytokine storm, a very common reaction in patients with COVID-19, but also in other pathologies such

David Segarra, an aptamer technology entrepreneur, co-founded aptaTargets in 2014 and has led the company to bring ApTOLL to the clinic. Previously, he was co-founder and CEO of Aptus Biotech, an